March 9th, 2021 | 07:15 CET
BYD, BioNTech, Kleos Space: A new trend starts here
If you want to be successful on the stock market, you have to back those shares with prospects. Although an intact upward trend suggests that a story will be well received on the market, the fall height also increases with the price. Investors have recently had to experience this pain, especially with shares in the field of electromobility or hydrogen. Even vaccine hopefuls such as BioNTech have lost ground. Let us show you how the trend stocks are faring and which sector is only at the beginning of its trend!
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
CNE100000296 , US09075V1026 , AU0000015588
Table of contents:
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
BYD and the fear of the future
BYD's stock lost over 20% last month. The Chinese electric carmaker has recently had to contend with a considerable downturn. With its battery cell production and access to numerous critical raw materials in China, it is perfectly positioned to profit from the trend. But after a 275% return in one year, every share is ripe for a correction.
The current inflationary trends are weighing on companies with a high growth perspective in particular. The reason: future profits could be lower as a result of inflation. Prices for raw materials in trend industries such as electromobility are also more likely to rise. This upsets the growth models, as increasing costs lead either to lower margins or higher prices. While BYD remains promising for the future, the stock is currently in correction mode - investors should not hope for better times but actively manage their trend stock portfolio.
BioNTech: Good products, weakening share price
Investors in BioNTech may also see a reason to act: The share recently dropped significantly and lost around 17% in one month. Over the year, the return is currently "only" 145% - the former trend value has become a reality. Yet fundamentally, things do not look bad for the Company from Mainz: The Corona vaccine from BioNTech and Pfizer is proving to be effective and suitable for preventing transmission of the virus. Epidemiologically, this is good news. It is not without reason that government advisors in Germany have recently been calling for younger people with many contacts to be vaccinated with BioNTech. The general competence around the mRNA process also speaks for the Company. The products are good, but the share is currently no longer a trend value.
Kleos Space: Satellites as data collectors
So, where should speculative investors move to? An attractive alternative is the share of Kleos Space. The stock has been stable for months and seems to have found a solid base. These are good conditions for a sustained rise in the share price, and this is all the more true given the extremely exciting investment story. Kleos Space operates satellites, collects data with them and sells them to companies and government organizations. Four satellites were launched into orbit at the end of last year. This summer and next December, more satellites will go into orbit, the Company announced yesterday.
With the help of a global network of satellites, Kleos Space wants to analyze data, such as radio activity, and make it available to its customers. In this way, for example, piracy or even illegal border crossings and smuggling are to be effectively prevented. Kleos Space also wants to make its data available to NGOs. Even with the satellites currently orbiting the earth, it is possible to monitor prominent regions. For this reason, Kleos Space has already signed twenty contracts and letters of intent with customers. These include the military, government agencies and companies.
Analysts see a 90% chance
Kleos Space itself has little competition outside the United States, citing high entry barriers for the space business. On the one hand, satellites must be developed and data collected processed, but on the other hand, entering the market is very costly. Kleos Space has successfully raised capital in the past and is already known to professional investors. Since a data subscription is expected to cost between EUR 60,000 and EUR 300,000, the Company, listed in Australia and Germany and headquartered in Luxembourg, expects to see rapidly increasing cash flows. Kleos Space is an exciting investment story. If the business takes off as planned, the Company can operate without much competition and make money for a long time. Analysts at First Berlin see a potential of up to AUD 1.15. Currently, the share is trading at AUD 0.60. Those who want to be in on the next trend early should analyze the value thoroughly and consider an entry.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
